Trial: 202009216

A Firstin-human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3



Principal Investigator

Morgensztern, Daniel

Disease Site

Lung; Prostate; Rectum; Small Intestine; Thyroid; Urinary Bladder

Learn more about this study at: